Immunohistochemical Assessment of Peripheral Squamous Lung Cancer: Comparison to Central Squamous Cell Carcinoma and Peripheral Adenocarcinoma

Jae Jun Kim; Jae Kil Park; Young Pil Wang

doi:10.6058/jlc.2009.8.2.99

Journal List > J Lung Cancer > v.8(2) > 1050712

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim, Park, and Wang: Immunohistochemical Assessment of Peripheral Squamous Lung Cancer: Comparison to Central Squamous Cell Carcinoma and Peripheral Adenocarcinoma

Original Article

J Lung Cancer 2009;8(2):99-102.

Published online: 10 January 2009

DOI: https://doi.org/10.6058/jlc.2009.8.2.99

Immunohistochemical Assessment of Peripheral Squamous Lung Cancer: Comparison to Central Squamous Cell Carcinoma and Peripheral Adenocarcinoma

Jae Jun Kim, M.D., Jae Kil Park, M.D., Young Pil Wang, M.D.

Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea

Address for correspondence Jae Kil Park, M.D. Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, 505, Ban-po-dong, Seocho-gu, Seoul 137-701, Korea Tel: 82-2-2258-6133 Fax: 82-2-594-8644 E-mail: jaekpark@catholic.ac.kr

Received 8 October 2009 Revised 6 November 2009 Accepted 13 November 2009

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

Incidence of peripheral squamous cell carcinoma (pSCCs) of the lung has increased over recent years, but the immunohistochemical factors involved in pSCCs have not been well established. The aim of this study was to analyze the immunohistochemical differences between pSCCs and central-type SCCs (cSCCs), and similarities between pSCCs and peripheral adenocarcinomas (pADCs).

Materials and Methods

In this retrospective study, we investigated the expression of three potential prognostic factors (p53, Ki-67, t-CEA), and two potential therapeutic targets (epidermal growth factor receptor [EGFR], and c-erbB-2) in 263 surgically resected cases of primary SCC and pADCs of the lung from January 2001 to July 2008. We divided the SCCs between peripheral and central types, and compared the expression rates of markers between pSCCs and cSCCs, and between pSCCs and pADCs.

Results

In this study, there were 149 pADC cases, and among the 114 SCC cases, there were 41 pSCCs (36.0%). There were significantly higher expression rates of Ki-67 and EGFR in pSCCs than in cSCCs or pADCs (p=0.003, p=0.039, respectively).

Conclusion

We found immunohistochemical differencies in pSCCs from cSCCs and pADCs.

Keywords: Lung neoplasms, Immunohistochemical study, Malignant diseases

References

1. Hammar SP, Brambilla E, Pugatch B, et al. Squamous cell carcinoma. Travis WD, Brambilla E, Muller-hermelink HK, Harris CC, editors. Pathology and genetics of tumours of the lung, pleura, thymus, and heart. Lyon: IARC Press;2004. p. 26–30.

2. Asamura H, Nakayama H, Kondo H, Tsuchiya R, Shimosato Y, Naruke T. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, nonsmall-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? J Thorac Cardiovasc Surg. 1996; 111:1125–1134.

3. Tomasshefski JF Jr, Connors AF Jr, Rosenthal ES, Hsiue IL. Peripheral vs central squamous cell carcinoma of the lung. A comparison of clinical features, histopathology, and survival. Arch Pathol Lab Med. 1990; 114:468–474.

4. Funai K, Yokose T, Ishii G, et al. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol. 2003; 27:978–984.

5. Kushihashi T, Munechika H. Histologic classification and radiologic manefestation of lung cancer. Jpn J Diagn Imaging. 1994; 16:379–390.

6. Takahasi T. Squamous cell carcinomas in the periphery of the lung: cell types and roentgenological findings. Jpn J Lung Cancer. 1984; 24:183–194.

7. Zwirewich CV, Vedal S, Miller RR, Mü ller NL. Solitary pulmonary nodule: high-resolution CT and radiologic-pathologic correlation. Radiology. 1991; 179:469–476.

8. el-Torkey M, Giltman LI, Dabbous M. Collagens in scar in carcinoma of the lung. Am J Pathol. 1985; 121:322–326.

9. Tokuda H. Morphological features of peripherally originating squamous cell carcinoma of the lung. Jpn J Lung Cancer. 1990; 30:963–973.

10. Sakurai H, Asamura H, Watanabe S, Suzuki K, Tsuchiya R. Clinicopathologic features of peripheral squamous cell carcinoma of the lung. Ann Thorac Surg. 2004; 78:222–227.

11. Demoly P, Pujol JL, Godard P, Michel FB. Oncogenes and anti-oncogenes in lung cancer. Presse Med. 1994; 23:291–297.

12. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol. 1998; 16:1207–1217.

13. Osada H, Takahashi T. Pathophysiology of lung cancer. Saishin Igaku. 1997; 52:12–18.

14. Harpole DH Jr, Richards WG, Herndon JE 2nd, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I nonsmall cell lung cancer. Ann Thorac Surg. 1996; 61:1470–1476.

15. Sadoff L. The usefulness of carcinoembryonic antigen testing in the overall management of patients with nonsmall cell lung cancer. Am J Clin Oncol. 1998; 21:284–286.

16. Veronesi G, Pelosi G, Sonzogni A, et al. Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung. Lung Cancer. 2005; 48:233–240.

17. Kern JA, Filderman AE. Oncogenes and growth factors in human lung cancer. Clin Chest Med. 1993; 14:31–41.

Tables

Table 1.

Materials

Group	Cytology	n (%)
	Squamous cell carcinoma	114
I	pSCCs	41 (36%)
II	cSCC	73 (64%)
	Adenocarcinoma	149
III	pADCs	149 (100%)
Total		263

pSCCs: peripheral squamous cell carcinomas, cSCCs: central squamous cell carcinomas, pADCs: peripheral adenocarcinomas

Table 2.

Positive Rates of Various Tumor Markers and Statistical Differences among the Groups

Tumor markers	Cytology	Positive rate (%)
p53	pSCCs	63
	cSCCs	54	p=0.301
	pADCs	41	p=0.062
Ki-67	pSCCs	93
	cSCCs	75	p=0.077
	pADCs	55	p=0.003
t-CEA	pSCCs	70
	cSCCs	70	p=0.500
	pADCs	81	p=0.223
EGFR	pSCCs	100
	cSCCs	71	p=0.039
	pADCs	80	p=0.074
c-erbB-2	pSCCs	31
	cSCCs	50	p=0.137
	pADCs	45	p=0.178

EGFR: epidermal growth factor receptor

TOOLS

Similar articles